logo-loader
viewShield Therapeutics PLC

Shield Therapeutics remain optimistic about US commercialisation of Accrufer in the US

Shield Therapeutics PLC (LON:STX) Chief Executive Tim Watts joins Proactive London's Katie Pilbeam to discuss their financial and operational update.

Watts highlights the European sales volumes of its breakthrough iron deficiency drug Feraccru which grew by 70% year-on-year.

He concentrates on the discussions that are ongoing with potential US out-licensing partners for Accrufer in the States (Feraccru).

Quick facts: Shield Therapeutics PLC

Price: 41 GBX

LSE:STX
Market: LSE
Market Cap: £48.22 m
Follow

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Shield Therapeutics PLC named herein, including the promotion by the Company of Shield Therapeutics PLC in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Shield Therapeutics: US commercial strategy for Accrufer and extension of...

Proactive analyst Emma Ulker discusses Shield Therapeutics PLC (LON:STX) which has updated on its commercialisation plan for the US market for its oral treatment Accrufer to treat iron deficiency.  While the company has engaged with a range of potential commercial partners for Accrufer,...

on 11/12/20

2 min read